An Observational Post-Authorization Safety Surveillance (PASS) Study of Sycrest (Asenapine) Among Patients Aged 18 and Older Diagnosed With Bipolar Disorder.
Phase of Trial: Phase IV
Latest Information Update: 11 May 2017
At a glance
- Drugs Asenapine (Primary) ; Olanzapine; Risperidone
- Indications Bipolar disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 03 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.
- 03 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2017.
- 26 May 2016 Status changed from active, no longer recruiting to recruiting.